Scientists at the University of Cambridge have announced the development of what is being described as the First Universal Vaccine candidate designed entirely with the help of artificial intelligence and successfully tested in humans, marking a major milestone in global efforts to prevent future pandemics.
Key Highlights:
- Scientists develop the First Universal Vaccine candidate using artificial intelligence.
- Vaccine designed to protect against current and future coronavirus strains.
- AI analysed genetic data from multiple coronaviruses to create a broad-protection antigen.
- Initial human trial involving 39 participants completed successfully.
- Larger study with about 200 volunteers currently underway.
- Researchers exploring similar AI-designed vaccines for influenza, bird flu and Ebola.
The experimental vaccine aims to provide protection against a wide range of coronaviruses, including existing COVID-19 variants and future strains that could potentially jump from animals to humans.
Researchers say the breakthrough could transform vaccine development by moving beyond traditional methods that focus on known virus strains. Instead, artificial intelligence was used to analyse genetic information from numerous coronaviruses identified through global surveillance programmes and design a “super-antigen” capable of training the immune system to recognise an entire family of related viruses.
Leading the research team, Professor Jonathan Heeney described the project as a critical step towards preventing future health crises before they occur.
“We’re always behind when responding to outbreaks. What we’re trying to do is get ahead of the curve and create vaccines that protect against future pandemics before they happen,” Heeney said.
Unlike conventional vaccines, which are tailored to specific virus variants, the First Universal Vaccine candidate is designed to remain effective even as viruses evolve, mutate or new strains emerge.
The vaccine has already completed an initial safety trial involving 39 participants. Researchers are now conducting a larger clinical study involving approximately 200 volunteers to assess how effectively it stimulates immune protection.
Read also:
- Cancer cure: Russia to pioneer mRNA Melanoma Vaccine with human trials set for fall 2025
- 3 Ebola vaccines in development amid growing outbreak fears
- Viral claims linking mRNA COVID-19 Vaccines to infertility debunked by scientific evidence
According to findings published in the Journal of Infection, early trials produced a modest immune response. However, scientists believe the underlying technology represents a major advancement in pandemic preparedness.
Professor Saul Faust, who participated in the human trials, described the early results as promising and said artificial intelligence has the potential to dramatically improve both the speed and accuracy of vaccine development.
Building on the success of the project, the Cambridge research team is already applying the same AI technology to develop universal influenza vaccines that could eliminate the need for annual vaccine updates.
Researchers are also exploring AI-designed vaccines targeting H5N1 bird flu and viral haemorrhagic diseases such as Ebola.
Experts not directly involved in the study have welcomed the findings. Professor Andy Pollard said the technology is generating compelling scientific evidence and could fundamentally reshape vaccine development by predicting immune responses more effectively.
Professor Marian Knight described the achievement as a significant milestone in the search for broad and long-lasting protection against infectious diseases.
Meanwhile, UK Science Minister David Vallance praised the project as a powerful example of how artificial intelligence and scientific research can work together to accelerate medical innovation.
Researchers believe AI-powered vaccine development could dramatically reduce the time required to create vaccines during future outbreaks, potentially saving millions of lives and strengthening global readiness against emerging infectious diseases.
